Citius Oncology (NASDAQ:CTOR) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Citius Oncology (NASDAQ:CTOR) issued its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. The firm had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $2.50 million.

Citius Oncology Stock Performance

Citius Oncology stock traded up $0.08 during midday trading on Friday, hitting $0.91. The stock had a trading volume of 257,395 shares, compared to its average volume of 122,617. The firm’s fifty day moving average is $0.68 and its two-hundred day moving average is $0.82. The company has a market capitalization of $84.59 million, a PE ratio of -1.94 and a beta of 3.48. Citius Oncology has a 52-week low of $0.49 and a 52-week high of $2.25. The company has a current ratio of 0.50, a quick ratio of 0.12 and a debt-to-equity ratio of 0.11.

Hedge Funds Weigh In On Citius Oncology

Several large investors have recently added to or reduced their stakes in CTOR. Geode Capital Management LLC increased its stake in shares of Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after purchasing an additional 36,758 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Citius Oncology during the 2nd quarter valued at $465,000. Bank of America Corp DE lifted its stake in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after buying an additional 8,411 shares in the last quarter. Citadel Advisors LLC bought a new position in Citius Oncology in the 3rd quarter worth $36,000. Finally, Armistice Capital LLC bought a new position in Citius Oncology in the 3rd quarter worth $15,582,000. Hedge funds and other institutional investors own 70.52% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.